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Introduction: Lung cancer is the leading cause of cancer death in
men and women, and current second-line chemotherapy regimens
yield relatively poor response and survival rates.
Hypothesis: We hypothesized that the combination of weekly
docetaxel (D) and gemcitabine (G) would show activity in the
second-line setting. We therefore conducted a phase II trial evalu-
ating this regimen in patients with relapsed or progressive non-small
cell lung cancer (NSCLC) after first-line platinum-based therapy.
Methods: Patients with recurrent NSCLC, adequate physiologic indi-
ces, and exposure to one prior platinum-based regimen were eligible.
Docetaxel 40 mg/m2 intravenous (IV) and gemcitabine (G) 800 mg/m2
IV weekly were administered on day 1 and 8 every 21 days. In the
absence of dose-limiting toxicity, G was escalated on an intrapatient
basis to 1 g/m2/wk. The primary endpoint was response rate (RR);
event-free (EFS) and overall survival were secondary endpoints.
Results: Thirty-five patients (median age 61 years; 20 [57%] male)
were accrued. Most (88%) had previously received carboplatin/
paclitaxel, 31.4% in combination with a third investigational agent,
more than half (57.1%) had prior radiation. The median number of
cycles was four. RR was 23%. Median EFS was 5.7 months and
median overall survival was 12.5 months. Patients who had their
cancer diagnosed more than or equal to 12 months before entering
the trial had superior EFS (13.7 months versus 4.8 months). Toxicity
was acceptable. There were no treatment-related deaths.
Conclusions: A nonplatinum doublet with GD is feasible and
effective in the treatment of recurrent, platinum-exposed NSCLC
patients. RR and survival are promising.
Key Words: Recurrent lung cancer, Gemcitabine, Docetaxel, Sec-
ond-line therapy.
(J Thorac Oncol. 2008;3: 1032–1038)
Lung cancer is the leading cause of cancer-related death inmen and women. The American Cancer Society has esti-
mated that the number of new lung cancer cases in the United
States will be 114,690 in men and 100,330 in women for 2008.
Among them, 161,840 are expected to die from this disease.
Treatment of advanced stage lung cancer is evolving, with the
development of new biologic therapies, such as erlotinib and
bevacizumab, adding to the therapeutic arsenal, both in the first
and second line. Nevertheless, a platinum-based doublet is still
the cornerstone of first-line therapy in non-small cell lung
cancer. The estimated 1-year survival with a platinum-based
doublet is approximately 30 to 35%1 and median time to pro-
gression remains poor at about 3 months. Second-line therapy is
indicated at the time of progression in patients with good
performance status, and it has become the standard of care in
non-small cell lung cancer patients who have experienced dis-
ease progression after first-line therapy.
Docetaxel has had an established role as second-line
therapy for nearly a decade. Based on two separate phase III
trials that showed a survival advantage compared with either
best supportive care (BSC) or to ifosfamide or vinorelbine,
it was the first Food and Drug Administration-approved
agent for salvage therapy in the United States. A study by
Shepherd et al.2 using single agent docetaxel showed time
to progression of 10.6 weeks compared with 6.7 weeks in
the BSC control group in patients with recurrent lung
cancer with a threefold improvement in 1-year survival
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rate for the docetaxel group (37%) compared with the BSC
group (11%). A second trial by Fossella et al.3 demonstrated
no difference in median survival times, but a 10% improve-
ment in 1-year survival rate for docetaxel 75 mg/m2 com-
pared with either ifosfamide or vinorelbine. Weekly do-
cetaxel has resulted in similar efficacy compared with a
conventional every 3-week schedule with improved toxicity
profile.4 A subsequent study in chemotherapy-naive lung
cancer patients using docetaxel and cisplatin treatment
resulted in response rate (RR) of 31.6% and median
survival of 11.3 months compared with RR of 24.5% and
median survival of 10.1 month in the vinorelbine and
cisplatin control arm.5
Before the recent approvals of Erlotinib and Pem-
etrexed as single agents in 2004 for second-line treatment,
gemcitabine seemed to be an equally promising agent in this
setting. A nonplatinum doublet of docetaxel and gemcitabine
constituted a logical choice for investigation in the second-
line setting after prior use of platinum.
Gemcitabine is a nucleoside analog, initially tested in
lung cancer as first-line therapy. Single agent gemcitabine in
phase II trials resulted in RRs of 20% and median survival of
7 months.6,7 Combination of gemcitabine and cisplatin gen-
erated a RR of 30.4% and a median survival of 9.1 month,8
and proved superior to cisplatin alone, yielding FDA ap-
proval for gemcitabine with cisplatin in the frontline therapy
for non-small cell lung cancer (NSCLC).
The combination of docetaxel with gemcitabine has
shown promising results as first-line therapy. Phase I/II trials
established the respective maximum tolerated dose of do-
cetaxel weekly at 36 to 50 mg/m2 and gemcitabine at 800
mg/m2 to 1000 mg/m2 on day 1 and 8.9,10 Other studies
employed docetaxel at a bolus dose on day 1 of a 3-week
schedule with maximum tolerated dose of 60 mg/m2 to 80
mg/m2.11,12 Phase II trials yielded promising activity for this
combination in NSCLC,13,14 and a subsequent phase III trial
using this regimen comparing it with other platinum doublets
showed equivalent RR and reduced toxicity.15
Human epidermal receptor 2 (HER-2) is an important
prognostic marker in breast cancer.16 HER-2 is also expressed
in lung cancer17 and its overexpression is associated with
shorter survival.18 The monoclonal antibody trastuzumab
binds specifically to HER-2, and when combined with che-
motherapy, it has demonstrated significantly greater efficacy
compared with chemotherapy alone in patients with meta-
static breast cancer.19
Given the potential synergistic effect, studies have been
devised incorporating the use of trastuzumab with chemo-
therapy in the treatment of advanced lung cancer. Phase II
trials testing the combination of trastuzumab with standard
chemotherapy in non-small cell lung cancer showed feasibil-
ity for this approach with median and 1-year survival rates
matching or exceeding prior results in the absence of trastu-
zumab.20,21 Our intention was to graft this agent onto com-
bination of weekly gemcitabine and docetaxel in the second-
line setting, but we aborted this effort when the first 18
enrollees tested negative for HER-2-neu by either fluores-
cence in situ hybridization or immunohistochemistry. Hence,
we restricted our phase II study to the cytotoxic combination,
testing this nonplatinum doublet in recurrent lung cancer
patients. The primary endpoint was RR; secondary endpoints
included survival and event-free survival (EFS).
PATIENTS AND METHODS
Second-line patients with advanced NSCLC and prior
platinum exposure received combination of gemcitabine
and docetaxel on a weekly basis. Eligibility stipulated
pathologically diagnosed non-small cell lung cancer; progres-
sive disease after initial platinum-based chemotherapy with at
least a 28 day chemotherapy hiatus; Eastern Cooperative
Oncology Group (ECOG) performance status 0 to 1; no
active brain metastases (not on steroids and stable clinically
after radiation); expected survival of more than 6 months; and
no other concurrent invasive malignancies.
Treatment Plan
The treatment regimen consisted of docetaxel weekly at
40 mg/m2 and gemcitabine at 800 mg/m2 day 1 and 8 every
21 days. Patients with a history of prior radiotherapy were
started at a gemcitabine dose of 600 mg/m2 days 1 and 8
every 21 days. In the absence of dose-limiting toxicity, the
gemcitabine dose was escalated 200 mg/m2 per cycle to a
maximum dose of 1000 mg/m2 days 1 and 8. Patients were
treated with decadron 4 mg orally twice daily, the day
before, the day of, and the day after chemotherapy to
prevent capillary leak syndrome. Patients were to have
been assigned on the basis of HER-2 expression by immu-
nohistochemistry with possible confirmation by fluores-
cence in situ hybridization to either chemotherapy alone or
to combined chemotherapy and trastuzumab. We intended
to treat the group with negative HER-2 expression with the
combination of weekly docetaxel and gemcitabine alone.
The group with HER-2 overexpression was to have been
treated with chemotherapy in combination with trastu-
zumab. In the absence of measurable HER-2 expression in
the first 18 patients and given the lack of improved response
and survival for trastuzumab with chemotherapy over che-
motherapy alone reported in the literature, we suspended the
component of the trial that included trastuzumab and pro-
ceeded with chemotherapy alone in all enrollees.
Tumor measurements were obtained every two cycles.
Patients with stable disease or response continued treatment
up to six cycles, and at investigator discretion, in the absence
of cumulative toxicity or disease progression, patients could
continue treatment beyond six cycles. The study was open for
accrual at Fox Chase Cancer Center and other medical centers
participating in the Oncology Physicians Network, a clinical
trials consortium in the Delaware Valley.
Statistical Design and Analysis
The primary objective was to assess the RR of the
regimen determined by Response Evaluation Criteria in Solid
Tumors. A two-stage design was used for this study. A
proportion of patients with favorable response of less than
15% was considered to be of no interest. The new treatment
would be of interest if the proportion of patients with favor-
able response proved to be 35% or higher. Thirty-four pa-
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tients were needed to test the null hypothesis: P  0.15
against the alternative hypothesis: P  0.35 with 13% sig-
nificance and 95% power. The rationale for using the type I
error larger than the type II is given in Rogatko and Litwin,
JNCI 1996;88:462 Letter. The early stopping point was 17
patients. If only 0 to 1 favorable response were observed after
17 patients were accrued, then the null hypothesis would
have been accepted and the trial terminated. If six or more
patients with tumor response were observed when 17 evaluable
patients were accrued, then the alternative hypothesis would
be accepted and the trial terminated. The probability of early
stopping under the null was 0.28 and under the alternative
0.59. If the trial progressed until 34 patients were evaluated
and eight or more patients with favorable response were
observed, then the null hypothesis would be rejected.
RRs were determined for all patients in the study as part
of an intention to treat analysis, irrespective of the number of
cycles. Confidence limits for the maximum likelihood esti-
mate of the RR were determined using an exact calculation
based on a two-stage design (Litwin). All patients were
included in the survival analyses. The Kaplan-Meier product-
limit method was used to estimate median EFS, which was
determined as time from the start of treatment to either the
progression of disease (PD) or the date of death in the
absence of PD; patients were censored at date of last follow-
up. Differences in EFS by gender, radiation, and ECOG
status were also examined and assessed using the log-rank
test. Overall survival including median and 1-year survival
rates were determined as time from start of treatment to date
of death; living patients were censored at date of last follow-
up. All analyses were done using Statistical Analysis Soft-
ware. The study protocol and consent forms were approved
by research review committee and institutional review board
before the study was initiated.
RESULTS
Enrollment
A total of 35 patients from two separate institutions
were enrolled in the study, one more than the projected
sample size of 34. An additional patient was recruited be-
cause one patient received only one cycle of treatment when
a minimum of two were required for analysis. Following the
“intention to treat” principle, all 35 patients were included in
the analyses.
Patient Characteristics
Demographic characteristics are shown in Table 1. The
median time from initial diagnosis (TDx) to enrollment was
12.4 months (range  0.9 to 183.3 months). Median age was
61; there were no age limits. Men constituted 57% of enroll-
ees; an identical percentage previously underwent irradiation.
Median follow-up was 12.5 months.
Response to Treatment
A total of 170 cycles were administered to the 35
enrollees. The median number of cycles was 4 (range, 1–16).
RRs were determined for all 35 patients (intention to treat
cohort). None of the patients had a complete response; 8 had
a partial response (RR 23%, 95% confidence interval 12
to 39%). Of the eight patients who responded, two patients
had no PD at the last follow-up and six had experienced
disease progression or had died.
Event-Free Survival and Overall Survival
The median event-free survival was 5.7 months. (Fig-
ure 1) At 12 months after the start of treatment, the event-free
survival estimate was 37%. The median overall survival time
was 12.5 months (Figure 1). At 12 months, the overall
survival rate was 51.4%. The 2-year survival was 31%. Four
TABLE 1. Patient Characteristics
Patient Characteristics N %
Gender
Male 20 57.1
Female 15 42.9
Median age 61 yrs (range, 30–79)
Race
Caucasian 33 94.3
African American 2 5.7
Institution
FCCC 32 91.4
POHA 3 8.6
Stage
IIIB (with/without effusion) 8 (2/6) 23
IV 27 77
ECOG status
0 11 31.4
1 24 68.6
Prior radiation
Yes 20 57.1
No 10 42.9
Metastatic sites
Liver 5
Adrenal 3
Extrathoracic nodes 2
Paraspinal, bone, brain scalp muscle
pancreas pelvis
1 in each
site
Prior therapy
Prior chemotherapy regimens
Paclitaxel carboplatin 20 57
Docetaxel carboplatin 2 5.7
Docetaxel vinorelbine 1 2.8
Etoposide cisplatin 1 2.8
Paclitaxel carboplatin regimen  a
third agent
11 31.4
Tarceva/placebo 3 8.5
CP 547,632 2 5.7
Anti-VEGF 1 2.8
Oral VEGF 1 2.8
Bevacizumab 3 5.7
Gefitinib 1 8.5
Second-line therapya
Erlotinib 1
VEGF, vascular endothelial growth factor.
a One patient had erlotinib as second line and the protocol allowed patients that had
one prior chemotherapy. Erlotinib did not count as prior chemotherapy.
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participants remain alive, with follow-up dates of January
(n  2), February (n  1), and March (n  1) 2008.
Compliance with Treatment
Twelve patients (34%) completed at least six cycles
of therapy and two to four cycles were given to 60% of
patients. Four enrollees stopped treatment in the absence
of disease progression or untoward toxicity after 6 (1
patient), 10 (2 patients), and 16 (1 patient) cycles. Of all 35
patients on study, the median time on treatment was 88 days
(range, 34–329 days).
Reasons for treatment discontinuation included dis-
ease progression in 17 patients, withdrawal or refusal in 3
patients, intercurrent comorbidity precluding continuation
of therapy in 7 patients, need for palliative radiation
therapy in 1 patient, and completion of treatment assign-
ment in 4 patients. The details are in Table 2.
Patient Characteristics and Event-Free Survival
Differences in event-free survival by gender, ECOG
performance status, prior radiation therapy, time between
TDx and start of treatment, and age were assessed using the
log-rank test. There were no differences based on gender,
prior radiation therapy, performance status, or age. Neverthe-
less, improved EFS correlated with longer time from TDx to
the start of treatment: 13.7 months for TDx 12 months
compared with 4.8 months for TDx 12 months (log-rank
test P  0.031) (Figure 2).
HER-2 Expression Data
We were able to determine HER-2 expression in the
first 18 patients; all proved negative. Among these individu-
als, four (22%) had partial response, eight (44%) had stable
disease and six (33%) had PD on treatment. After 18 patients
had been accrued, and it was determined that none had
HER-2 expression, routine determination of HER-2 status
FIGURE 1. Overall survival and EFS. FIGURE 2. EFS by time since TDx.
TABLE 2. Reason for Discontinuation
Reason for Discontinuation N
Disease progression 17
Withdrawal or refusal Three including one patient who opted for observation without treatment
because of minimal disease
Intercurrent comorbidity precluding
continuation of therapy
Three (one with COPD, anemia, and pneumonia—one with hyponatremia,
SAIDH, pneumonia, and change in mental status, and one with grade 2
neuropathy persisting 3 wk)
Need for palliative radiation therapy One patient
Intercurrent toxicity Seven patients:
Ataxia and depression deemed possibly related, which proved intolerable
to one patient
Decrease in performance status deemed possibly related, in one patient
Patient and physician decision in one patient
Pneumonitis in two patients, in each case deemed definitely related
Skin toxicity considered definitely related in one patient
Leg edema deemed definitely related in one patient
Completion of assigned treatment Four patients
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was abandoned, and the component of the trial integrating
trastuzumab with gemcitabine and docetaxel was discarded.
Toxicity
Data for grades 3 and 4 toxicities that were felt to be
possibly, probably, or definitely related to the study treatment
are shown in Table 3. There were no disease-related deaths.
Hematological toxicity included 1 patient each with grade 3
anemia and thrombocytopenia, 15 patients with at least grade
3 neutropenia, and 6 patients with grade 4 neutropenia. There
was no exclusion for the use of growth factor, but only two
patients required G-cerebrospinal fluid, only one of whom
had neutropenic fever. Six grade 3 and two grade 4 infections
were observed on study. The infections were not related to
study treatment and were treated with per standard medical
care. None resulted in death.
DISCUSSION
We initiated a trial of weekly docetaxel schedule be-
cause of its reduced toxicity and similar efficacy compared
with the more conventional every 3-week schedule.4 Our
study yielded a RR of 23%, median survival of 12.5 months,
and event-free survival of 5.7 months. These results seem
comparable to several other phase II studies using docetaxel
and gemcitabine in combination as first-line therapy (Table
4). This combination, despite its use in the second-line
setting, did not cause severe toxicity; and there were no
treatment-related deaths.
Compared with historic controls, survival in this phase
II study compares favorably with the results of prior phase III
studies. BR-21, for example, orchestrated through the
NCI-C, compared single agent erlotinib to placebo and
showed a RR of 8.9%, progression free survival of 2.2
months and median survival of 6.7 months for the erlotinib
arm.29 In a phase III trial comparing pemetrexed to docetaxel
in patients with recurrent NSCLC, pemetrexed yielded a RR
of 9.1%, median progression free survival of 2.9 months, and
median survival of 8.3 months. Docetaxel yielded a RR of
8.8%, median progression of 2.9 months, and median survival
of 7.9 months.30
Whether the apparent improvement in outcome on our
phase II effort reflects the inherent superiority of this regimen
or instead represents selection bias or the effects of third and
fourth line therapy is open to speculation. We do not have
data on subsequent therapy and therefore cannot quantify the
extent of exposure to other therapies including pemetrexed or
erlotinib. This information would have been valuable in
determining the impact of additional therapy in the survival
of these patients. Moreover, the bulk of accrual came from a
single center, so unintentional selection bias may have influ-
enced outcomes. But it should be noted that there were no
competing second-line trials either at Fox Chase Cancer
Center or in Oncology Physicians Network at the time of this
study. In addition, all of these patients had intact performance
status (0 or 1) after initial chemotherapy and were very likely
in better shape clinically when compared with those enrolled
on other trials. Over 30% of those accrued to the BR-21
effort, for example, were PS 2 or 3, and about 11% enrolled
on the phase III trial comparing docetaxel with Pemetrexed
were PS 2. In addition, we showed that time from TDx to
start of treatment had a direct bearing on EFS: 13.7 months
versus 4.8 months for 12 months elapsed from diagnosis
versus 12 months. (P  0.037). This observation sug-
gests some degree of cross-resistance in those whose disease
has progressed quickly either during or immediately after
prior therapy.
Which therapy to choose in the second-line setting and
when to integrate targeted agents or chemotherapeutics re-
main unanswered. Recent phase III trials seem to suggest that
TABLE 3. Toxicity Summary, Grades 3 and 4, Treatment
Relation 3–5, n  35 Patients
Any
Grades
3–5 Grade 3 Grade 4
Treatment-Related Toxicity n % n % n %
Hemoglobin 3 8.6 3 8.6 0 0.0
ANC 15 42.9 9 25.7 6 17.1
Platelets 3 8.6 3 8.6 0 0.0
WBC 15 42.9 12 34.3 3 8.6
Neutropenic fever 1 2.9 1 2.9 — —
Infection with neutropenia 3 8.6 3 8.6 0 0.0
Infection without neutropenia 1 2.9 1 2.9 0 0.0
Edema 1 2.9 1 2.9 0 0.0
Tachycardia 1 2.9 1 2.9 0 0.0
Atrial fib 1 2.9 1 2.9 0 0.0
Orthostatic hypotension 2 5.7 2 5.7 0 0.0
Syncope 1 2.9 1 2.9 0 0.0
Rash 2 5.7 2 5.7 0 0.0
Constipation 1 2.9 1 2.9 0 0.0
Diarrhea 1 2.9 1 2.9 0 0.0
Vomiting 2 5.7 2 5.7 0 0.0
LFTs 3 8.6 3 8.6 0 0.0
Pain 1 2.9 1 2.9 0 0.0
Pleural effusion 2 5.7 2 5.7 0 0.0
Drug-induced pneumonitis 3 8.6 2 5.7 1 2.9
TABLE 4. Comparison with Other Studies
Current
Study
Bolus Docetaxel with
Gemcitabine15,22,23,24,25a
Weekly Docetaxel with
Gemcitabine26,27a
Weekly Docetaxel and Gemcitabine in
Elderly Patients28a
Response rate 24% 31–55% 20–36% 28%
Median survival 12.5 mo 8.5–11.1 mo 6.9–11.3 mo 7 mo
a First-line therapy.
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both chemotherapy and targeted therapies yield similar effi-
cacy, albeit with significant differences in toxicity. Recent
studies with targeted combinations have yielded improved
RRs and reasonably acceptable toxicity profiles. This is
exemplified by the Erlotinib and Bevacizumab doublet,
which yielded a RR of 18% and 1-year survival rate of 57%
compared with a RR of 12% and 1-year survival rate of 33%
with chemotherapy alone.31
The natural concern with combined chemotherapy is
toxicity, but if a novel combination can yield higher RRs and
longer survival, many clinicians are willing to accept in-
creased levels of toxicity as long as the regimen remains
tolerable. A nonplatinum doublet is a viable option in good
performance status patients who have had prior platinum expo-
sure and it may ultimately prove to be the regimen of choice
when treating recurrent disease after adjuvant chemotherapy
with a platinum doublet, which has emerged as a standard of
care based on recent trials.32,33,34
We conclude that the nonplatinum doublet of docetaxel
and gemcitabine in the second-line setting is feasible and
capable of producing a reasonable RR and prolonged EFS
and overall survival. But, it still begs the question as to how
this combination would compare with either the constituent
single agents or new therapeutic combinations (erlotinib,
pemetrexed, or bevacizumab). Given the results observed in
our effort, a phase III trial comparing the weekly regimen of
gemcitabine and docetaxel to standard docetaxel alone or to
other second-line agents alone should be considered. Unfor-
tunately, the appetite for such an effort in the new era of
targeted therapy is very likely limited.
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